share_log

B of A Securities Maintains Buy on Lyell Immunopharma, Lowers Price Target to $6

B of A Securities Maintains Buy on Lyell Immunopharma, Lowers Price Target to $6

美國銀行證券維持對Lyell免疫治療的買入評級,將目標價下調至6美元。
Benzinga ·  06/27 13:28

B of A Securities analyst Geoff Meacham maintains Lyell Immunopharma (NASDAQ:LYEL) with a Buy and lowers the price target from $9 to $6.

B of A Securities的分析師Geoff Meacham維持Lyell Immunopharma(納斯達克:LYEL)的買入評級,將目標價格從9美元下調至6美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論